Changes in Beneficial Ownership · 4

Imunon, Inc.

IMNNNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Aug 17, 2026Accepted Aug 17, 2026, 4:21 PM EDTFiling CIK 749647Accession 0001437749-26-028186

View company →Permanent SEC source ↗

Structured filing — 4

rdgdoc.xml

Open full document ↗

Filing details

Report period: 2026-08-14
Issuer: Imunon, Inc.
Issuer CIK: 0000749647
Trading symbol: IMNN

Reporting owner 1

Name: Faller Douglas Vincent
Reporting owner CIK: 0002056033
Relationship: Officer
Officer title: Chief Medical Officer
Address: C/O IMUNON, INC., 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE, NJ, 08648

Non-derivative transactions

Non-derivative transactions · 1 reported row
Security	Transaction date	Code	Amount	A / D	Price (USD)	Owned after	Ownership
Common Stock	2026-08-14	A · Form 4	3,516^[F1]	A	1.65	33,451	D

Table key

A · Form 4: Acquisition by grant, award or otherwise under Rule 16b-3(d)
A: Acquired
D: Direct

Footnotes

F1: Stock granted in lieu of cash for portion of base salary↩ 1

Signature 1

Signed: /s/ Susan Eylward, Attorney-in-Fact for Douglas Faller
Date: 2026-08-17

Company context

Imunon is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms with the aim to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases.

Current securities

IMNNNASDAQ · EQUITY · Current

Get the free weekly BCS email.